GlassScriptPhysician profile
Cynthia Chambers
NPI 1518278357
$5,405.18
in general payments reported to CMS, 2019-2025
21 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $134 · 2021: $104 · 2022: $208 · 2023: $2,830 · 2024: $857 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686 · Travel and Lodging: $1,001 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.05 |
| Travel and Lodging | $1,000.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,581.86 | 2019-2023 | Xeomin |
| Abbvie INC. | $1,278.30 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $715.92 | 2019-2025 | |
| Galderma Laboratories, L.P. | $670.26 | 2019-2025 | |
| Leo Pharma INC. | $232.03 | 2020-2025 | Adbry |
| Incyte Corporation | $143.24 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $127.26 | 2023-2025 | Sotyktu |
| Amgen INC. | $101.12 | 2019-2025 | Otezla, Otezla |
| Allergan, INC. | $92.30 | 2021-2022 | |
| Ucb, INC. | $90.64 | 2019-2025 | Bimzelx |
| Celgene Corporation | $81.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $50.27 | 2019-2021 | |
| Dermavant Sciences, INC. | $49.12 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.38 | 2022 | |
| Genzyme Corporation | $32.73 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $28.04 | 2024 | Vyjuvek |
| Janssen Biotech, INC. | $26.48 | 2019 | |
| Pfizer INC. | $26.34 | 2023 | |
| Dusa Pharmaceuticals, INC. | $17.81 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.77 | 2021 | |
| Organon LLC | $1.65 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.